Ron Branning has 50 years’ experience in the Bio/Pharmaceutical Industry. Ron is Co-Founder of GXPQS and as the former CEO, he was the principal consultant for the transition from Clinical to Commercial (GMP, GDP) aspects of the consulting services. Ron also had primary responsibility for management oversight and governance of the deliverables to clients. His previous position was Senior VP of Quality at Dermira. His other industry positions have been Chief Quality Officer for Genzyme, VP Corporate Quality and Compliance Officer for Gilead and Global SVP Quality for Genentech. He brings a wealth of worldwide Quality experience in devices, drugs, biologics, and biotechnology and combination products in virtually all dosage forms. Ron’s career has been focused on resolution of significant quality issues and implementing Quality Systems that are designed to ensure compliance and rapid new product approval.

Ron began his career in 1968 with J&J and began consulting as Ron Branning Consulting LLC, Quality Systems Compliance in 2007. He has served as Head of Corporate Quality for Genzyme, Gilead, Genentech, Aventis Behring, Somatogen and Serono. His other Quality management positions have been with Genetics Institute, Boehringer Ingelheim, GD Searle and Johnson and Johnson.

Ron graduated with a BBA industrial management from the University of Texas, Commerce in 1973 and was enrolled in the MBA Program at the University of Dallas in 1974 -1975.

Ron has participated in numerous seminars and workshops and delivered many papers and presentations to industry organizations covering production, quality, regulatory and validation topics. In addition to the many industry committees and task forces he has chaired, Ron has been a member of the ISPE International Leadership Forum, a member of the Scientific Advisory Board, Peking University MBA Program, Beijing China as well as President and board member of ISPE’s Boston Area Chapter and PDA Texas Chapter board member.